<< Back To Search

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study is looking at a new treatment for people with multiple myeloma who have not responded well to other treatments. It involves taking three drugs together: ibrutinib, lenalidomide, and dexamethasone. Men and women are invited to participate.
*Third Opinion AI Generated Synopsis

Trial Summary
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?